Achillion Pharmaceuticals (NASDAQ:ACHN) focus on the discovery and development of therapies for infectious diseases

Boston, MA, 07/15/2013 (nysepost) – During the last trading session, the shares of Achillion Pharmaceuticals (NASDAQ:ACHN) were bought by insiders. One of the most notable purchases was made by QVT Associates GP LLC which holds a 10% stake in Achillion Pharmaceuticals, having bought a total number of 390,944 shares for the price of $ 2,475,223. Achillion Pharmaceuticals is a company focused on infectious disease therapeutic area.

During the last trading session, the stock of Achillion Pharmaceuticals has shown an increase of 1.62% and was trading with an average volume of 1.59 million shares at the value of $ 6.29. During the past 12 months, Achillion Pharmaceuticals has generated an income of $ -49.70 million with sales of $ 0.10 million. For the past 12 months, the analytic ratios of the company are as follows: price to sales ratio and price to cash ratio were calculated as 5314.12 and 3.66 respectively. The return on equity ratio of Achillion Pharmaceuticals stood at -49.40% while its return on assets was -44.60%.

More recently, after the bell Monday, Achillion Pharmaceuticals, Inc. has made an announcement that the company’s drug, “sovaprevir” is placed on a clinical hold by FDA after elevations found in liver enzymes. Following this, stock of Achillion Pharmaceuticals has plunged to more than 10-month low.

Achillion Pharmaceuticals is a biopharmaceutical company which has its focus on the discovery and development of therapies for infectious diseases which include anti-virals for chronic hepatitis C infection and anti-bacterials for resistant bacterial infections. The company has four drug candidates in its pipeline against HCV treatment: ACH-1625 – currently in phase IIa clinical trial, ACH-2684 and ACH-2928 – currently in phase I clinical studies, ACH-3102 – currently in the preparation for IND-filing and for entering into phase I studies.

Achillion Pharmaceuticals has a pipeline of other drug candidates and is currently seeking for collaborative partners. The company did not find the resources to develop ACH-702 and ACH-2881 which are potential against resistant bacterial infections and elvucitabine against HIV infection.

About the Author

Mary Calhun financial reporter NYSE post. Authors have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. This article is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. *NYSE Post does not set price targets on securities. Never invest into a stock discussed on this website unless you can afford to lose your entire investment.